T-cell alloimmunity and chronic allograft dysfunction

Kidney International

Volumn 78, Issue SUPPL. 119, 2010, Pages

  Safinia, Niloufar ^a   Afzali, Behdad ^a   Atalar, Kerem ^a   Lombardi, Giovanna ^a   Lechler, Robert I ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

allorecognition; human; regulatory T cell; Th17; transplantation

Indexed keywords

ALEMTUZUMAB; ANTIBODY; B LYMPHOCYTE RECEPTOR; CD20 ANTIBODY; CD25 ANTIBODY; CD3 ANTIBODY; CYCLOPHOSPHAMIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TRANSFER; CELLULAR IMMUNITY; CHIMERA; CHRONIC ALLOGRAFT DYSFUNCTION; CONFERENCE PAPER; DENDRITIC CELL; GRAFT DYSFUNCTION; HUMAN; KIDNEY GRAFT REJECTION; MYELOABLATIVE CONDITIONING; NONHUMAN; NONMYELOABLATIVE CONDITIONING; ORGAN TRANSPLANTATION; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TRANSPLANTATION TOLERANCE; VACCINATION;

EID: 78649662954     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.416     Document Type: Conference Paper

References (133)

1. Cecka JM. The UNOS Renal Transplant Registry. Clin Transpl 2002: 1-20.
2. Starzl TE, Klintmalm GB, Weil III R et al. Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet 1981; 153: 486-494.
3. Waller JR, Nicholson ML. Molecular mechanisms of renal allograft fibrosis. Br J Surg 2001; 88: 1429-1441.
4. Matas AJ, Gillingham KJ, Sutherland DE. Half-life and risk factors for kidney transplant outcome-importance of death with function. Transplantation 1993; 55: 757-761.
5. Cornell LD, Colvin RB. Chronic allograft nephropathy. Curr Opin Nephrol Hypertens 2005; 14: 229-234.
6. Joosten SA, van Kooten C, Paul LC. Pathogenesis of chronic allograft rejection. Transpl Int 2003; 16: 137-145.
7. Yates PJ, Nicholson ML. The aetiology and pathogenesis of chronic allograft nephropathy. Transpl Immunol 2006; 16: 148-157.
8. Solez K, Colvin RB, Racusen LC et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518-526.
9. Marsh SG, Albert ED, Bodmer WF et al. Nomenclature for factors of the HLA system, 2004. Tissue Antigens 2005; 65: 301-369.
10. Apostolopoulos V, Lazoura E, Yu M. MHC and MHC-like molecules: structural perspectives on the design of molecular vaccines. Adv Exp Med Biol 2008; 640: 252-267.
11. Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol 1993; 11: 385-402.
12. Takatsuki M, Uemoto S, Inomata Y et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001; 72: 449-454. (Pubitemid 32769631)
13. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006; 6: 1774-1780.
14. Tisone G, Orlando G, Cardillo A et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006; 44: 702-709.
15. Calne RY, Sells RA, Pena JR et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969; 223: 472-476.
16. Kamada N. The immunology of experimental liver transplantation in the rat. Immunology 1985; 55: 369-389.
17. Warrens AN, Lombardi G, Lechler RI. Presentation and recognition of major and minor histocompatibility antigens. Transpl Immunol 1994; 2: 103-107.
18. Whitelegg A, Barber LD. The structural basis of T-cell allorecognition. Tissue Antigens 2004; 63: 101-108.
19. Lechler RI, Batchelor JR. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982; 155: 31-41.
20. Herrera OB, Golshayan D, Tibbott R et al. A novel pathway of alloantigen presentation by dendritic cells. J Immunol 2004; 173: 4828-4837.
21. Snell GD. The homograft reaction. Annu Rev Microbiol 1957; 11: 439-458.
22. Talmage DW, Woolnough JA, Hemmingsen H et al. Activation of cytotoxic T cells by nonstimulating tumor cells and spleen cell factor(s). Proc Natl Acad Sci USA 1977; 74: 4610-4614.
23. Talmage DW, Dart G, Radovich J, Lafferty KJ. Activation of transplant immunity: effect of donor leukocytes on thyroid allograft rejection. Science 1976; 191: 385-388.
24. Bowen KM, Andrus L, Lafferty KJ. Successful allotransplantation of mouse pancreatic islets to nonimmunosuppressed recipients. Diabetes 1980; 29(Suppl 1): 98-104.
25. Pietra BA, Wiseman A, Bolwerk A et al. CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II. J Clin Invest 2000; 106: 1003-1010.
26. Baker RJ, Hernandez-Fuentes MP, Brookes PA et al. The role of the allograft in the induction of donor-specific T cell hyporesponsiveness. Transplantation 2001; 72: 480-485.
27. Rogers NJ, Lechler RI. Allorecognition. Am J Transplant 2001; 1: 97-102.
28. Lombardi G, Sidhu S, Daly M et al. Are primary alloresponses truly primary? Int Immunol 1990; 2: 9-13.
29. Merkenschlager M, Ikeda H, Wilkinson D et al. Allorecognition of HLA-DR and -DQ transfectants by human CD45RA and CD45R0 CD4 T cells: repertoire analysis and activation requirements. Eur J Immunol 1991; 21: 79-88.
30. Crispe IN, Husmann LA, Bevan MJ. T cell receptor expression and receptor-mediated induction of clonal growth in the developing mouse thymus. High surface beta-chain density is a requirement for functional maturity. Eur J Immunol 1986; 16: 1283-1288.
31. Matzinger P, Bevan MJ. Hypothesis: why do so many lymphocytes respond to major histocompatibility antigens? Cell Immunol 1977; 29: 1-5.
32. Schneck J, Munitz T, Coligan JE et al. Inhibition of allorecognition by an H-2 Kb-derived peptide is evidence for a T-cell binding region on a major histocompatibility complex molecule. Proc Natl Acad Sci USA 1989; 86: 8516-8520.
33. Villadangos JA, Galocha B, Lopez de Castro JA. Unusual topology of an HLA-B27 allospecific T cell epitope lacking peptide specificity. J Immunol 1994; 152: 2317-2323.
34. Lombardi G, Barber L, Sidhu S et al. The specificity of alloreactive T cells is determined by MHC polymorphisms which contact the T cell receptor and which influence peptide binding. Int Immunol 1991; 3: 769-775.
35. Smith PA, Brunmark A, Jackson MR, Potter TA. Peptide-independent recognition by alloreactive cytotoxic T lymphocytes (CTL). J Exp Med 1997; 185: 1023-1033.
36. Ely LK, Kjer-Nielsen L, McCluskey J, Rossjohn J. Structural studies on the alphabeta T-cell receptor. IUBMB Life 2005; 57: 575-582.
37. Turner SJ, Doherty PC, McCluskey J, Rossjohn J. Structural determinants of T-cell receptor bias in immunity. Nat Rev Immunol 2006; 6: 883-894.
38. Eckels DD, Gorski J, Rothbard J, Lamb JR. Peptide-mediated modulation of T-cell allorecognition. Proc Natl Acad Sci USA 1988; 85: 8191-8195.
39. Rotzschke O, Falk K, Faath S, Rammensee HG. On the nature of peptides involved in T cell alloreactivity. J Exp Med 1991; 174: 1059-1071.
40. Kuzushima K, Sun R, van Bleek GM et al. The role of self peptides in the allogeneic cross-reactivity of CTLs. J Immunol 1995; 155: 594-601.
41. Barber LD, Gillece-Castro B, Percival L et al. Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes. Curr Biol 1995; 5: 179-190.
42. Hornick PI, Mason PD, Yacoub MH et al. Assessment of the contribution that direct allorecognition makes to the progression of chronic cardiac transplant rejection in humans. Circulation 1998; 97: 1257-1263.
43. Lechler RI, Batchelor JR. Immunogenicity of retransplanted rat kidney allografts. Effect of inducing chimerism in the first recipient and quantitative studies on immunosuppression of the second recipient. J Exp Med 1982; 156: 1835-1841.
44. Inaba K, Turley S, Yamaide F et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 1998; 188: 2163-2173.
45. Auchincloss H, Lee R, Shea S et al. The role of 'indirect' recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci USA 1993; 90: 3373-3377.
46. Essaket S, Fabron J, de Preval C, Thomsen M. Corecognition of HLA-A1 and HLA-DPw3 by a human CD4+ alloreactive T lymphocyte clone. J Exp Med 1990; 172: 387-390.
47. de Koster HS, Anderson DC, Termijtelen A. T cells sensitized to synthetic HLA-DR3 peptide give evidence of continuous presentation of denatured HLA-DR3 molecules by HLA-DP. J Exp Med 1989; 169: 1191-1196.
48. Kievits F, Ivanyi P. A subpopulation of mouse cytotoxic T lymphocytes recognizes allogeneic H-2 class I antigens in the context of other H-2 class I molecules. J Exp Med 1991; 174: 15-19.
49. Hunt DF, Michel H, Dickinson TA et al. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 1992; 256: 1817-1820.
50. Lee RS, Grusby MJ, Glimcher LH et al. Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. J Exp Med 1994; 179: 865-872.
51. Fangmann J, Dalchau R, Fabre JW. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. Transplant Proc 1993; 25(1 Part 1): 183-184. (Pubitemid 23082321)
52. Sayegh MH, Perico N, Gallon L et al. Mechanisms of acquired thymic unresponsiveness to renal allografts. Thymic recognition of immunodominant allo-MHC peptides induces peripheral T cell anergy. Transplantation 1994; 58: 125-132.
53. Valujskikh A, Lantz O, Celli S et al. Cross-primed CD8(+) T cells mediate graft rejection via a distinct effector pathway. Nat Immunol 2002; 3: 844-851.
54. Valujskikh A, Zhang Q, Heeger PS. CD8 T cells specific for a donor-derived, self-restricted transplant antigen are nonpathogenic bystanders after vascularized heart transplantation in mice. J Immunol 2006; 176: 2190-2196.
55. Steele DJ, Laufer TM, Smiley ST et al. Two levels of help for B cell alloantibody production. J Exp Med 1996; 183: 699-703.
56. Taylor AL, Negus SL, Negus M et al. Pathways of helper CD4 T cell allorecognition in generating alloantibody and CD8 T cell alloimmunity. Transplantation 2007; 83: 931-937.
57. Noorchashm H, Reed AJ, Rostami SY et al. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol 2006; 177: 7715-7722.
58. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 474-478.
59. Game DS, Rogers NJ, Lechler RI. Acquisition of HLA-DR and costimulatory molecules by T cells from allogeneic antigen presenting cells. Am J Transplant 2005; 5: 1614-1625.
60. Morelli AE, Larregina AT, Shufesky WJ et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 2004; 104: 3257-3266.
61. Smyth LA, Afzali B, Tsang J et al. Intercellular transfer of MHC and immunological molecules: molecular mechanisms and biological significance. Am J Transplant 2007; 7: 1442-1449.
62. Pimenta-Araujo R, Mascarell L, Huesca M et al. Embryonic thymic epithelium naturally devoid of APCs is acutely rejected in the absence of indirect recognition. J Immunol 2001; 167: 5034-5041.
63. Mandelbrot DA, Kishimoto K, Auchincloss H et al. Rejection of mouse cardiac allografts by costimulation in trans. J Immunol 2001; 167: 1174-1178.
64. Larsen CP, Steinman RM, Witmer-Pack M et al. Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med 1990; 172: 1483-1493.
65. Lakkis FG, Arakelov A, Konieczny BT, Inoue Y. Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 2000; 6: 686-688.
66. Sandner SE, Salama AD, Houser SL et al. New TCR transgenic model for tracking allospecific CD4 T-cell activation and tolerance in vivo. Am J Transplant 2003; 3: 1242-1250.
67. Reed AJ, Noorchashm H, Rostami SY et al. Alloreactive CD4 T cell activation in vivo: an autonomous function of the indirect pathway of alloantigen presentation. J Immunol 2003; 171: 6502-6509.
68. Bal V, McIndoe A, Denton G et al. Antigen presentation by keratinocytes induces tolerance in human T cells. Eur J Immunol 1990; 20: 1893-1897.
69. Lombardi G, Arnold K, Uren J et al. Antigen presentation by interferon-gamma-treated thyroid follicular cells inhibits interleukin-2 (IL-2) and supports IL-4 production by B7-dependent human T cells. Eur J Immunol 1997; 27: 62-71.
70. Marelli-Berg FM, Weetman A, Frasca L et al. Antigen presentation by epithelial cells induces anergic immunoregulatory CD45RO+ T cells and deletion of CD45RA+ T cells. J Immunol 1997; 159: 5853-5861.
71. Marelli-Berg FM, Hargreaves RE, Carmichael P et al. Major histocompatibility complex class II-expressing endothelial cells induce allospecific nonresponsiveness in naive T cells. J Exp Med 1996; 183: 1603-1612.
72. Malissen M, Trucy J, Letourneur F et al. A T cell clone expresses two T cell receptor alpha genes but uses one alpha beta heterodimer for allorecognition and self MHC-restricted antigen recognition. Cell 1988; 55: 49-59.
73. Marelli-Berg FM, James MJ, Dangerfield J et al. Cognate recognition of the endothelium induces HY-specific CD8+ T-lymphocyte transendothelial migration (diapedesis) in vivo. Blood 2004; 103: 3111-3116.
74. Grimm PC, Nickerson P, Jeffery J et al. Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N Engl J Med 2001; 345: 93-97.
75. Kapessidou Y, Habran C, Buonocore S et al. The replacement of graft endothelium by recipient-type cells conditions allograft rejection mediated by indirect pathway CD4+ T cells. Transplantation 2006; 82: 582-591.
76. Atalar K, Afzali B, Lord G, Lombardi G. Relative roles of Th1 and Th17 effector cells in allograft rejection. Curr Opin Organ Transplant 2009; 14: 23-29.
77. O'Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010; 327: 1098-1102.
78. McGeachy MJ, Cua DJ. Th17 cell differentiation: the long and winding road. Immunity 2008; 28: 445-453.
79. Tay SS, Plain KM, Bishop GA. Role of IL-4 and Th2 responses in allograft rejection and tolerance. Curr Opin Organ Transplant 2009; 14: 16-22.
80. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25: 821-852.
81. Szabo SJ, Kim ST, Costa GL et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100: 655-669.
82. Ivanov II, McKenzie BS, Zhou L et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126: 1121-1133.
83. Martin-Fontecha A, Thomsen LL, Brett S et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004; 5: 1260-1265.
84. Sawitzki B, Kingsley CI, Oliveira V et al. IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med 2005; 201: 1925-1935.
85. O'Connell PJ, Pacheco-Silva A, Nickerson PW et al. Unmodified pancreatic islet allograft rejection results in the preferential expression of certain T cell activation transcripts. J Immunol 1993; 150: 1093-1104.
86. Nickerson P, Steurer W, Steiger J et al. Cytokines and the Th1/Th2 paradigm in transplantation. Curr Opin Immunol 1994; 6: 757-764.
87. Miura M, El-Sawy T, Fairchild RL. Neutrophils mediate parenchymal tissue necrosis and accelerate the rejection of complete major histocompatibility complex-disparate cardiac allografts in the absence of interferon-gamma. Am J Pathol 2003; 162: 509-519.
88. Gras J, Wieers G, Vaerman JL et al. Early immunological monitoring after pediatric liver transplantation: cytokine immune deviation and graft acceptance in 40 recipients. Liver Transpl 2007; 13: 426-433.
89. Sadeghi M, Daniel V, Naujokat C et al. Evidence for IFN-gamma up- and IL-4 downregulation late post-transplant in patients with good kidney graft outcome. Clin Transplant 2007; 21: 449-459.
90. Hoffmann SC, Hale DA, Kleiner DE et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant 2005; 5: 573-581.
91. Alcaide P, Jones TG, Lord GM et al. Dendritic cell expression of the transcription factor T-bet regulates mast cell progenitor homing to mucosal tissue. J Exp Med 2007; 204: 431-439.
92. Townsend MJ, Weinmann AS, Matsuda JL et al. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity 2004; 20: 477-494.
93. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148: 32-46.
94. Loong CC, Hsieh HG, Lui WY et al. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol 2002; 197: 322-332.
95. Van Kooten C, Boonstra JG, Paape ME et al. Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol 1998; 9: 1526-1534.
96. Antonysamy MA, Fanslow WC, Fu F et al. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 1999; 162: 577-584.
97. Yuan X, Ansari MJ, D'Addio F et al. Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc Natl Acad Sci USA 2009; 106: 10734-10739.
98. Yuan X, Paez-Cortez J, Schmitt-Knosalla I et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008; 205: 3133-3144.
99. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
100. Sakaguchi S, Wing K, Miyara M. Regulatory T cells-a brief history and perspective. Eur J Immunol 2007; 37(Suppl 1): S116-S123.
101. Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol 2007; 120: 744-750; quiz 751-2.
102. Ochs HD, Gambineri E, Torgerson TR. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol Res 2007; 38: 112-121.
103. Hall BM, Pearce NW, Gurley KE, Dorsch SE. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action. J Exp Med 1990; 171: 141-157.
104. Graca L, Cobbold SP, Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med 2002; 195: 1641-1646.
105. Aramaki O, Shirasugi N, Akiyama Y et al. Induction of operational tolerance and generation of regulatory cells after intratracheal delivery of alloantigen combined with nondepleting anti-CD4 monoclonal antibody. Transplantation 2003; 76: 1305-1314.
106. Sanchez-Fueyo A, Domenig CM, Mariat C et al. Influence of direct and indirect allorecognition pathways on CD4+CD25+ regulatory T-cell function in transplantation. Transpl Int 2007; 20: 534-541.
107. Mirenda V, Berton I, Read J et al. Modified dendritic cells coexpressing self and allogeneic major histocompatability complex molecules: an efficient way to induce indirect pathway regulation. J Am Soc Nephrol 2004; 15: 987-997.
108. Quezada SA, Fuller B, Jarvinen LZ et al. Mechanisms of donor-specific transfusion tolerance: preemptive induction of clonal T-cell exhaustion via indirect presentation. Blood 2003; 102: 1920-1926.
109. Hara M, Kingsley CI, Niimi M et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166: 3789-3796.
110. Hornick PI, Mason PD, Baker RJ et al. Significant frequencies of T cells with indirect anti-donor specificity in heart graft recipients with chronic rejection. Circulation 2000; 101: 2405-2410.
111. Wise MP, Bemelman F, Cobbold SP, Waldmann H. Linked suppression of skin graft rejection can operate through indirect recognition. J Immunol 1998; 161: 5813-5816.
112. Game DS, Hernandez-Fuentes MP, Chaudhry AN, Lechler RI. CD4+CD25+ regulatory T cells do not significantly contribute to direct pathway hyporesponsiveness in stable renal transplant patients. J Am Soc Nephrol 2003; 14: 1652-1661.
113. Salama AD, Najafian N, Clarkson MR et al. Regulatory CD25+ T cells in human kidney transplant recipients. J Am Soc Nephrol 2003; 14: 1643-1651.
114. Toyokawa H, Nakao A, Bailey RJ et al. Relative contribution of direct and indirect allorecognition in developing tolerance after liver transplantation. Liver Transpl 2008; 14: 346-357.
115. Taflin C, Miyara M, Nochy D et al. FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. Am J Pathol 2009; 174: 497-508.
116. Taflin C, Nochy D, Hill G et al. Regulatory T cells in kidney allograft infiltrates correlate with initial inflammation and graft function. Transplantation 2010; 89: 194-199.
117. Zuber J, Brodin-Sartorius A, Lapidus N et al. FOXP3-enriched infiltrates associated with better outcome in renal allografts with inflamed fibrosis. Nephrol Dial Transplant 2009; 24: 3847-3854.
118. Callaghan CJ, Rouhani FJ, Negus MC et al. Abrogation of antibody-mediated allograft rejection by regulatory CD4 T cells with indirect allospecificity. J Immunol 2007; 178: 2221-2228.
119. Sykes M, Sachs DH. Mixed allogeneic chimerism as an approach to transplantation tolerance. Immunol Today 1988; 9: 23-27.
120. Kawai T, Cosimi AB, Spitzer TR et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 353-361.
121. Ochando JC, Homma C, Yang Y et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 2006; 7: 652-662.
122. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5: 1219-1226.
123. Villadangos JA, Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 2008; 29: 352-361.
124. Nikolic T, Welzen-Coppens JM, Leenen PJ et al. Plasmacytoid dendritic cells in autoimmune diabetes - potential tools for immunotherapy. Immunobiology 2009; 214: 791-799.
125. Tanriver Y, Ratnasothy K, Bucy RP et al. Targeting MHC class I monomers to dendritic cells inhibits the indirect pathway of allorecognition and the production of IgG alloantibodies leading to long-term allograft survival. J Immunol 2010; 184: 1757-1764.
126. Kirk AD, Burkly LC, Batty DS et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686-693.
127. Clatworthy MR, Watson CJ, Plotnek G et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 360: 2683-2685.
128. Tyden G, Genberg H, Tollemar J et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87: 1325-1329.
129. Jiang S, Camara N, Lombardi G, Lechler RI. Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex vivo. Blood 2003; 102: 2180-2186.
130. Tsang JY, Tanriver Y, Jiang S et al. Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest 2008; 118: 3619-3628.
131. Joffre O, Santolaria T, Calise D et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008; 14: 88-92.
132. Afzali B, Mitchell P, Lechler RI et al. Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells. Clin Exp Immunol 2010; 159: 120-130.
133. Trzonkowski P, Bieniaszewska M, Juscinska J et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin Immunol 2009; 133: 22-26.